Zilia is a medical device company that prevents, diagnose, and treats various ocular, neurological, and systemic conditions.
Zilia has developed a non-invasive platform technology that uses imaging, spectrometry and artificial intelligence to quantitatively measure different biomarkers in the human eye. Zilia’s initial product, Zilia Ocular, is the first retinal camera to quantify oxygen saturation, a crucial biomarker in ocular diseases such as glaucoma, DR and AMD. Zilia aims to revolutionize the prevention, diagnosis and management of these diseases by generating actionable data about the eye’s metabolic activity.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 11, 2021 | Seed | $4M | 2 | Anges Quebec | — | Detail |
Jun 25, 2019 | Non-Equity Assistant | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Anges Quebec | Yes | Seed |
Investissement Quebec | — | Seed |
Creative Destruction Lab (CDL) | — | Non-Equity Assistant |